Janssen Turns To High Court In Bid To Block Zytiga Generics

By Matthew Bultman (November 21, 2018, 5:09 PM EST) -- Janssen Biotech Inc. said on Tuesday it was going to sprint to the U.S. Supreme Court after the Federal Circuit refused to block sales of generic versions of Zytiga while Janssen appeals a ruling that invalidated a patent on the blockbuster oncology medication....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!